GLAXO SEEKS TO MARKET WELLBUTRIN UNDER SECOND BRAND NAME FOR SMOKING CESSATION; FDA COMMITTEE UNANIMOUSLY RECOMMENDS APPROVAL OF NEW INDICATION
Glaxo Wellcome is asking FDA to approve the use of a different brand name for marketing of its antidepressant Wellbutrin SR (bupropion) as an aid to smoking cessation. Glaxo has submitted at least two names for FDA consideration.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth